Cariprazine
- Generic Name
- Cariprazine
- Brand Names
- Vraylar, Reagila
- Drug Type
- Small Molecule
- Chemical Formula
- C21H32Cl2N4O
- CAS Number
- 839712-12-8
- Unique Ingredient Identifier
- F6RJL8B278
- Background
Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT receptors and as an antagonist at serotonin 5-HT receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipo...
- Indication
Cariprazine is indicated for the treatment of schizophrenia in adults to manage both positive and negative symptoms. It is also indicated to monotherapy for acute management of manic or mixed episodes associated with bipolar I disorder (bipolar mania) in adults, and acute management of depressive episodes associated with bipolar I disorder (bipolar depressio...
- Associated Conditions
- Bipolar Disorder With Manic or Mixed Episodes, Depressive Episodes, Schizophrenia
- Associated Therapies
- -
Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression
- First Posted Date
- 2009-02-26
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 234
- Registration Number
- NCT00852202
- Locations
- ๐บ๐ธ
Forest Investigative Site 026, Orlando, Florida, United States
๐บ๐ธForest Investigative Site 005, Encino, California, United States
๐บ๐ธForest Investigative Site 006, Media, Pennsylvania, United States
A Study of Cariprazine in Patients With Chronic Stable Schizophrenia
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 97
- Registration Number
- NCT00839852
- Locations
- ๐ท๐บ
Forest Investigative Site 214, St. Petersburg, Russian Federation
๐ท๐บForest Investigative Site 202, St. Petersburg, Russian Federation
๐ท๐บForest Investigative Site 203, St. Petersburg, Russian Federation
Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2019-06-12
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 732
- Registration Number
- NCT00694707
- Locations
- ๐ท๐บ
Forest Investigative Site 1, Moscow, Russian Federation
๐บ๐ฆForest Investigative Site, Kiev, Ukraine
๐ท๐บForest Investigative Site 2, St. Petersburg, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.